The role of meta-iodo ( sup 131 I)benzylguanidine (MIBG) in the diagnosis and follow-up of neuroblastoma

Journal Article · Wed Jan 01 00:00:00 EST 1986 · Pediatric Hematology and Oncology; (USA)

DOI:https://doi.org/10.3109/08880018609031199· OSTI ID:6070818

Miceli, A; Nespoli, L; Burgio, G R; Aprile, C; Carena, M; Saponaro, R ^[1]

---

1. Univ. of Pavia (Italy)

Fourteen scans employing the adrenergic blocking agent ({sup 131}I)MIBG were performed on 10 children with neuroblastoma (NB) or ganglioneuroblastoma (GNB). The scans were negative in 5 cases, and 1 further case produced doubtful results in both the MIBG and CT scan tests. In 4 cases, very positive results were obtained with clear vision of the primary tumor and its metastases. In 1 case, which demonstrated partial differentiation of the outer part of the tumor mass toward GNB, a differentiated tumor specimen did not reveal significant uptake of the tracer. Half-lives of the tracer as measured by external detection in the period 24-48 h after injection were reduced after successful therapy. MIBG scanning appears to be a feasible indicator of NB adrenergic activity, and it can assume a primary role in the staging and follow-up of NB. Higher tumor uptake of the ({sup 131}I)MIBG and low background offer new perspectives in the radiometabolic treatment of MIBG.

• OSTI ID: 6070818
• Journal Information: Pediatric Hematology and Oncology; (USA), Vol. 3:1; ISSN 0888-0018
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
AUTONOMIC NERVOUS SYSTEM
NEOPLASMS
DIAGNOSIS
RADIOPHARMACEUTICALS
UPTAKE
BIOLOGICAL HALF-LIFE
CHILDREN
IODINE 131
METABOLISM
AGE GROUPS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
NERVOUS SYSTEM
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
550601* - Medicine- Unsealed Radionuclides in Diagnostics